Compare INTZ & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTZ | FEMY |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1M | 11.5M |
| IPO Year | 2020 | 2021 |
| Metric | INTZ | FEMY |
|---|---|---|
| Price | $0.41 | $1.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | ★ 173.6K | 97.6K |
| Earning Date | 11-12-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.78 | 44.71 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,015,000.00 | $2,293,313.00 |
| Revenue This Year | $22.62 | N/A |
| Revenue Next Year | $26.44 | $328.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 21.56 | ★ 40.77 |
| 52 Week Low | $0.47 | $0.29 |
| 52 Week High | $1.56 | $6.29 |
| Indicator | INTZ | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 34.65 | 39.05 |
| Support Level | N/A | $1.26 |
| Resistance Level | $0.89 | $3.21 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 3.15 | 52.88 |
Intrusion Inc is a cybersecurity company based in Plano, Texas. The company offers its customers access to its exclusive threat intelligence database containing the historical data, known associations, and reputational behavior of Internet Protocol addresses. Its platform combines threat intelligence, malicious traffic identification, and automated threat response, and is designed to help organizations proactively identify and stop malicious activity in their networks. Its solutions include INTRUSION Shield, INTRUSION TraceCop, and INTRUSION Savant. The company operates in single segment.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.